ondansetron has been researched along with Hemorrhagic Shock in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ondansetron treatment restored phos-p38 MAPK expression as compared with vehicle-treated haemorrhaged rats." | 1.37 | Ondansetron attenuates hepatic injury via p38 MAPK-dependent pathway in a rat haemorrhagic shock model. ( Liu, FC; Liu, FW; Yu, HP, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, FC | 1 |
| Liu, FW | 1 |
| Yu, HP | 1 |
1 other study available for ondansetron and Hemorrhagic Shock
| Article | Year |
|---|---|
Ondansetron attenuates hepatic injury via p38 MAPK-dependent pathway in a rat haemorrhagic shock model.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Chemokine CXCL1; Chemokine CXCL2; Cytoki | 2011 |